US Stock MarketDetailed Quotes

NLSP NLS Pharmaceutics

Watchlist
  • 1.9500
  • -0.4300-18.07%
Close Dec 20 16:00 ET
  • 1.9000
  • -0.0500-2.56%
Post 20:01 ET
4.62MMarket Cap-0.29P/E (TTM)

About NLS Pharmaceutics Company

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.

Company Profile

SymbolNLSP
Company NameNLS Pharmaceutics
Listing DateJan 29, 2021
Issue Price4.15
Founded2015
CEOMr. Alexander Zwyer
MarketNASDAQ
Employees4
Fiscal Year Ends12-31
AddressThe Circle 6
CityZurich
ProvinceZurich
CountrySwitzerland
Zip Code8058
Phone41-44-512-21-50
Websitehttp://www.nlspharma.com

Company Executives

  • Name
  • Position
  • Salary
  • Alexander Zwyer
  • Chief Executive Officer and Director
  • --
  • Dr. Eric Konofal, M.D.
  • Chief Scientific Officer
  • --
  • George Apostol
  • Chief Medical Officer and Global Head of Research and Development
  • --
  • Elena Thyen-Pighin
  • Chief Financial Officer and Head of Finance and Human Resources
  • --
  • Ronald Hafner
  • Chairman of the Board
  • --
  • Audrey Greenberg
  • Independent Director
  • --
  • Gian-Marco Rinaldi
  • Independent Director
  • --
  • Claudio L. A. Bassetti
  • Independent Director
  • --
  • Florence Allouche Aknin
  • Independent Director
  • --
Heat List
US
Overall
Symbol
Price
% Chg

No Data